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Ischemic heart disease (IHD) is one of the primary causes of death around the world.
Therapeutic angiogenesis is a promising innovative approach for treating IHD, improving
cardiac function by promoting blood perfusion to the ischemic myocardium. This
treatment is especially important for targeting patients that are unable to undergo
angioplasty or bypass surgery. Chinese herbal medicines have been used for more
than 2,500 years and they play an important role alongside contemporary medicines in
China. Growing evidence in animal models show Chinese herbal medicines can provide
therapeutic effect on IHD by targeting angiogenesis. Identifying the mechanism in which
Chinese herbal medicines can promote angiogenesis in IHD is a major topic in the
field of traditional Chinese medicine, and has the potential for advancing therapeutic
treatment. This review summarizes the progression of research and highlights potential
pro-angiogenic mechanisms of Chinese herbal medicines in IHD. In addition, an outline
of the limitations of Chinese herbal medicines and challenges they face will be presented.
Keywords: ischemic heart disease, treatment status, Chinese herbal medicines, therapeutic angiogenesis,
targets
INTRODUCTION
Ischemic heart disease (IHD), also called coronary artery disease (CAD) (Jaganathan et al.,
2014), refers to the condition of stenosis or obstruction of the lumen of arteries and inadequate
blood supply to the myocardium leading to myocardial ischemia (MI), hypoxia or necrosis.
Clinically, IHD includes asymptomatic MI, angina, myocardial infarction, ischemic heart failure
and sudden cardiac death (Wong, 2014). IHD is reported to be the leading reason of disability
and death worldwide which caused 8.9 million deaths in 2015, resulting in a large economic
burden to the medical community (GBD 2015 Mortality and Causes of Death Collaborators,
2016). Although several risk factors including high blood pressure, smoking, diabetes, lack of
exercise, obesity and high blood cholesterol have been identified (Charlson et al., 2013; Mehta et al.,
2015), the therapeutic effects are still limited. Therefore, new treatment strategies mitigating the
deleterious effects of IHD are being explored intensively. Growing evidence suggest the potential
pro-angiogenic benefits of Chinese herbal medicines in IHD. This review will summarize the status
and process of the pro-angiogenic roles and mechanism of Chinese herbal medicines in IHD. In
addition, the limitations and future challenges will be highlighted.
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METHODOLOGY
The United States National Library of Medicine, National
Institutes of Health (NIH) database1 was searched with the
terms “IHD” or “therapeutic angiogenesis” or “Chinese herbal
medicines” in the “title/abstract” field. Related articles were
chosen manually before 31st December, 2017. All articles which
had an abstract available were included. No language restrictions
were applied.
TREATMENT STATUS OF ISCHEMIC
HEART DISEASE
The front line clinical treatments for IHD include drug therapy,
percutaneous coronary intervention (PCI) and coronary artery
bypass grafts (CABGs). There are a number of pharmaceutical
therapies which are widely used in IHD including nitroglycerin
(Boden et al., 2015), statins (Gutierrez et al., 2012), β-blockers
(Bauters et al., 2014), and calcium channel blockers (Conti, 2011)
but their beneficial effects are limited. In some cases symptoms
are still are not significantly improved even upon maximal dosage
of drug therapy (Pogosova et al., 2016). PCI is a minimal invasive
procedure to treat stenosis of the coronary arteries. A deflated
balloon catheter is advanced into an obstructed artery via the
saphenous or radial artery. Inflation of the balloon reverses the
narrowing of the blood vessel (Osorio et al., 2017). Alternatively,
stents are placed in the narrowed artery to ensure blood vessels
remain dilated. PCI is restricted to patients whose angiography
do not show arteries <1.5 mm in diameter or display diffusely
diseased saphenous vein grafts (Montalescot et al., 2014). CABG
is a surgical strategy to improve the coronary perfusion and
used to treat patients who have severe IHD. During this process,
sections of saphenous vein and radial artery are usually used as
the vascular bridge. The blood bypasses the lesion of coronary
artery and flows to the ischemic myocardium through the
vascular bridge. However, the patency of the grafted artery or
vein depends on the patient’s vascular status and is likely to
be atherosclerotic similar to the coronary vessels. Furthermore,
due to the invasive nature it is not a viable procedure in
elderly patients, e.g., octogenarians and above (Ohki et al., 2002).
Approximately 12% of patients with IHD are unsuited to the
classical PCI or CABG treatment (Tandar et al., 2002). This is due
to diffuse disease, chronic total occlusion, multiple stenosis, poor
targets and severe comorbidities (Mitsos et al., 2012). Therapeutic
angiogenesis has attracted great interest in targeting patients that
are not viable for the current treatment. Increasing blood supply
to the ischemic zone is fundamental to the treatment of IHD.
Therefore, therapeutic angiogenesis is the promising approach
aimed at returning cardiac function (Sasaki et al., 2002; Koneru
et al., 2008). The applications of growth factor therapy, gene
therapy and stem cell therapy are becoming more widely used.
Recent findings have indicated that Chinese herbal medicines
may be effective in the treatment of IHD by promoting
angiogenesis. Focus has turned to pre-clinical investigations to
1https://www.ncbi.nlm.nih.gov/pubmed/
understand the mechanism in which Chinese herbal medicines
can induce angiogenesis in IHD. In this review, we summarize
current data on the pro-angiogenic role of Chinese herbal
medicines in IHD. The review focuses on the research process
and prospects of traditional Chinese herbal medicines in
therapeutic angiogenesis for IHD.
BASIC MECHANISMS OF
ANGIOGENESIS
Three important processes are required for the development
of the vascular system, vascular network formation during
embryonic development (vasculogenesis) (Schulte, 1914),
microvascular formation (angiogenesis) (Ausprunk and
Folkman, 1977; Carmeliet, 2000) and the formation of
larger arteries and vessels (arteriogenesis) (Heil et al., 2006).
Neovascularization is a term used to describe vessel development
(Freedman and Isner, 2001).
Angiogenesis refers to the development of new blood vessels
from pre-existing capillaries (Angulo et al., 2011). The process
of angiogenesis includes degradation of vascular basement
membrane; proliferation and migration of endothelial cells;
lumen structure and vascular network formation (Ren et al.,
2014). The mechanism of angiogenesis is complicated and
tightly regulation of different cell types, such as endothelial
cells, smooth muscle cells, and inflammatory cells. Vascular
endothelial cells have the ability of rapid proliferation, migration
and differentiation in response to physiological stimulation
(Folkman, 1995b). There are many molecules involved in the
regulation of angiogenesis, including vascular endothelial growth
factor (VEGF), fibroblast growth factor (FGF), transforming
growth factor (TGF), tumor necrosis factor (TNF) and
angiopoietin-2, etc. VEGF is the most studied, and a large
number of pre-clinical experiments have proved that it is effective
in promoting angiogenesis. VEGF can activate a plethora of
downstream pathways including PI3K-Akt/mTORC2 pathway,
Raf-MEK-MAPK pathway and Src-FAK pathway (Matsumoto
and Claesson-Welsh, 2001; Claesson-Welsh, 2016) (Figure 1).
Tissue hypoxia or inflammation is major stimuli of angiogenesis.
In settings where angiogenesis is deficient administration of
recombinant proteins, or gene and stem cells therapies can
enhance the ability for angiogenesis to occur.
ISCHEMIC HEART DISEASE AND
ANGIOGENESIS
Angiogenic Growth Factor Therapy
Ischemic heart disease is caused by the stenosis or obstruction
of coronary blood vessels denying oxygen to the heart muscle.
Promoting the heart to generate new blood vessels through
angiogenesis provides a potential to combat IHD. Over the
last few decades this has been attempted mainly through the
delivering cytokines to increase blood perfusion in the ischemic
region and ultimately reverse the disease (Cooke and Losordo,
2015). Traditional cytokine-based therapies, such as VEGF,
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FIGURE 1 | VEGF signaling pathway involved in angiogenesis.
FGF, platelet-derived growth factor (PDGF) and angiopoietins,
have shown theoretical and experimental promises for treating
ischemic diseases (Harada et al., 1996; Atluri and Woo, 2008).
Vascular Endothelial Growth Factors
To date, VEGF is a recognized regulator of angiogenesis and
is an endothelial specific mitogen for IHD. The VEGF family
comprises of different isoforms, VEGF-A, VEGF-B, VEGF-C,
VEGF-D, and placental growth factor (PIGF) (Neufeld et al.,
1999). VEGF frequently refers to VEGF-A. VEGF-A contributes
to angiogenesis, vasculogenesis, and vascular homeostasis. In
contrast to VEGF-A, VEGF-B can’t regulate angiogenesis and
it functions in the muscle fatty acids uptake (Mehlem et al.,
2016). In addition, VEGF-C and VEGF-D regulate the lymph
system and adipose tissue inflammation (Karaman et al., 2015).
PIGF is synthesized mainly by trophoblast cells and can
bind to tyrosinase receptors in trophoblast cells and vascular
endothelial cells. PIGF mainly affects the function of trophoblast
cells through autocrine action, and influences the process of
vascular growth through paracrine action (Cao et al., 1997).
The receptors of VEGFs include VEGFR1 (Flt1), VEGFR2
(Flk1), and VEGFR3. VEGF can promote the proliferation,
migration, and angiogenesis of endothelial cells by promoting
the mitochondria function (Guo et al., 2017). It was shown
in porcine coronary occlusion model that VEGF treatment
increased blood flow and recovery of cardiac function (Harada
et al., 1996). Intracoronary VEGF treatment enhanced the
development of small coronary arteries supplying ischemic
myocardium in dogs (Banai et al., 1994). However, there are
many limitations in the administration of VEGF. VEGF may
induce the progression of atherosclerotic plaques (Celletti et al.,
2001). What’s worse, VEGF over-loading has the potential to
cause cancer (Hanahan and Folkman, 1996), diabetic retinopathy
(Aiello et al., 1994), and rheumatoid arthritis (Folkman,
1995a).
Fibroblastic Growth Factors
Fibroblastic growth factors are another important growth factors
in angiogenesis, wound healing and embryonic development. The
FGFs are heparin-binding proteins and interactions with cell
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TABLE 1 | Monomers and active components of medicinal plants in ischemic heart disease.
Classification Name Source Models Targets Reference
Replenishing and
activating blood
Salvianolic acid A Radix Salvia miltiorrhiza In vivo JNK/PI3K/Akt↓;
EPCs, MSCs↑
Guo et al., 2014; Li et al.,
2014; Chen et al., 2016
Tanshinone IIA Radix Salvia miltiorrhiza In vivo VEGF and HIF-1a↑ Xu et al., 2009
Ferulaic acid Radix Angelica Sinensis In vivo VEGF, AKT/mTOR↑ Liu et al., 2009; Zhang Q.
et al., 2017
Invigorating and
replenishing Qi
Rhodiola Rhizoma Rhodiolae Kirilowii In vivo Flt-1, Tie-2, HIF-1a,
HIF-1β↑
Li et al., 2005; Gao et al.,
2009
Salidroside Rhizoma Rhodiolae Kirilowii In vivo Unknown Zhang J. et al., 2017
Astragalosides Shanxi Astragalus membranaceus In vivo VEGF and bFGF↑ Yu et al., 2015
Other active
components of
medicinal plants
Berberine Berberis and Berberis aristata In vivo/
in vitro
miR-29b↑ Zhu et al., 2017
Puerarin Radix Puerariae In vivo VEGF and eNOS↑ Zhang S. et al., 2006
Extract of Geum japonicum Germ japonicum In vivo Unknown Li et al., 2006
surface-associated heparin sulfated proteoglycans. FGF-FGFR-1
is the most common signaling pathway. It has been reported
that vacation could stimulate the expression of FGF2, followed
by phosphorylation of FGFR-1 and promote angiogenesis
in microvascular endothelial cells (Sun et al., 2017). Up-
regulated FGF2/an early growth response protein 1(EGR1)
ameliorated cardiac ischemia and systolic dysfunction (Suda
et al., 2017). Endothelial FGFR pathways are beneficial for the
IHD. Conditional knock out of Fgfr1 and Fgfr2 in endothelial
cells attenuated cardiac function compared to control group in
myocardial model (House et al., 2016).
Angiopoietins
Angiopoietins are parts of vascular growth factors that play
an important role in angiogenesis. Angiopoietin cytokines are
involved in regulating microvascular permeability and vascular
tension. There are four identified angiopoietins: Ang-1, Ang-2,
Ang-3, and Ang-4. It has been reported that Ang-1, circulating
Ang-2 and Ang-2/Ang-1 ratio (Ang-2/1) were all increased at
ST-segment elevation myocardial infarction patients and were
related to the serious extend of myocardial damage (Chen et al.,
2012). Ang-4 could inhibit the activity of lipoprotein lipase which
could hydrolyze triglyceride, thus Ang-4 may be related to the
low risk of CAD (Dewey et al., 2016). Ang-2/Tie2 signaling
pathway is involved in angiogenesis in inflammatory cornea (Yan
et al., 2017). Ang-1, miR-1, and miR-206 functioned in hypoxic
induced myoblasts vascularization (Taylor et al., 2017).
Although angiogenic growth factor therapy attracts wide
attention, clinical trials for myocardial angiogenesis have
produced unstable effects. It is difficult to titer an effective
concentration of VEGF in humans and side-effects easily occur.
For example, VEGF could increase the permeability of the blood
vessels and cause diabetic retina disease. Although, VEGF has
been extensively studied further studies are required to gain
better efficacy and safety to enable therapeutic angiogenesis.
Gene Therapy
Various improvements in biological vector such as viruses
and small DNA have improved transmission and expression
efficacy of cytokines to enable clinical to promote angiogenesis
(Khan et al., 2003). The focus has mainly centered on the
use of FGF (FGF1 and FGF2), and VEGF A (VEGF-A165
and VEGF-A121). In preclinical studies, new gene transferring
techniques including recombinant adenovirus vectors and
liposome complexes have been shown to be effective in
promoting angiogenesis for myocardial and vascular diseases
(Maione et al., 2001). Recombinant adenovirus, co-expressing
antimicrobial peptide (PR39) and adrenomedullin (ADM) were
injected into infarcted myocardia and attenuated myocardial
injury by promoting angiogenesis (An et al., 2017). However,
the robustness and safety of gene therapy really deserve more
attention for this to become widely used in clinics.
Stem Cell Therapy
Stem cell therapy is also a promising option for treating IHD
and has beneficial effects via multiple mechanisms (Fukuda
et al., 2004). Autologous bone marrow cells, skeletal myoblasts,
embryonic stem cells, adult mesenchymal stem cells (MSCs), and
adult hematopoietic progenitor cells all have the potential to treat
IHD. Autologous bone marrow cells were transplanted into the
ischemic myocardium in five male patients. Cardiac function
and blood perfusion were improved demonstrating promising
potential for this therapy (Yoo et al., 2008). Autologous skeletal
myoblast transplantation in Phase I clinical studies demonstrated
feasibility in treatment of post infarction myocardial injury after
12 months of follow-up, (Siminiak et al., 2004). Crisostomo
et al. (2008) isolated Sprague–Dawley rat hearts in an ex vivo
Langendorff model and subjected them to ischemia/perfusion
treatment. Hearts treated with embryonic stem cells showed
better post ischemic recovery (Crisostomo et al., 2008). MSCs
with activation of Rap1 conferred cardioprotection against
myocardial infarction in rats (Khan et al., 2017). Likewise,
endothelial stem cells and MSCs also improve cardiac function
in this case via increasing vascular density (Rabbani et al.,
2017). Further studies will be required to determine the optimal
cell type, dose, transmission method. Moreover, the ability to
treatment time after ischemia will be important to develop the
effectiveness of the therapy.
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TABLE 2 | Chinese herbal formula in ischemic heart disease.
Name Composition Models Results/effects Reference
Danggui Buxue Tang (DBT) Astragalus, angelica In vitro Unknown Lin et al., 2017
Xuefu Zhuyu Tang (XFZYT) Peach kernel, safflower, angelica,
chuanqiong, radix paeoniae rubra
In vitro VEGF-VEGFR2↑ Gao et al., 2012
Buyang Huanwu Tang (BYHWT) Astragalus, angelica, radix
paeoniae rubrathe, peach kernel,
safflower, earthworm
In vivo VEGFR2-PI3K/Akt↑ Cui et al., 2015
TABLE 3 | Chinese patent drugs in ischemic heart disease.
Name Composition Models Results/effects Reference
Shexiang Baoxin pills Musk, ginseng extract, bezoar, cinnamon,
storax, borneol toad
In vivo 20-HETE, EPCs, and VEGF↑ Huang et al., 2017
QI-SHEN-YI-QI Astragalus, danshen, panax notoginseng,
dalbergia
In vivo VEGF, bFGF and PDGF-B↑;
miR-223-3p↓
Zhang et al., 2010; Dai
et al., 2016
Tongxinluo Ginseng, leech, scorpion, centipede,
cicada, wood louse insects, red peony root
In vivo PDGF, bFGF, ANG-1, and VEGF↑ Cui et al., 2016
Xuesetong soft capsules Notoginseng total saponins In vivo VEGF↑ Zang et al., 2014
Combined Therapy
Gene therapy and bone marrow MSCs therapy are commonly
combined. Qin et al. (2017) constructed recombinant adenovirus
vectors 5-hERL-IRES-VEGF (Ad5-EIV) combining reporter
gene hERL and therapeutic gene VEGF165. The recombinant
adenovirus vector was transfected into MSCs (Ad5-EIV-MSCs).
In a rat model of myocardial infarction Ad5-EIV-MSCs
were transplanted into the peripheral myocardium, effectively
preserving cardiac function (Qin et al., 2017). Another study also
indicated that CXCR4-overexpressing MSCs could repair heart
tissue post myocardial infarction by promoting angiogenesis
and alleviate left ventricle remodeling via paracrine signaling
mechanism (Wu et al., 2017).
CHINESE HERBAL MEDICINES
TARGETING ANGIOGENESIS IN
ISCHEMIC HEART DISEASE
Being able to manipulate neovascularization is central to treating
IHD. Chinese medicines have a basic view on vascular system for
years, such as the concepts of “bloodline and blood-collateral.”
Bloodline means larger blood vessels and blood-collateral means
the smaller vessels. Traditional Chinese medicine believes that
Qi is the most basic substance to make up the human body,
and Qi and blood are interlinked. Some scholars have identified
that Chinese herbal medicines with the action of activating Qi
and blood may function in promoting angiogenesis (Zang et al.,
2014). Increasing evidence has shown Chinese herbal medicines
may be effective in the treatment of IHD, especially Chinese
medicines with the effects of replenishing and activating blood
or invigorating and replenishing Qi. Chinese herbal medicine
monomers (Table 1), formula (Table 2) and Chinese patent
drugs (Table 3) all have shown some benefit in stimulating
revascularization, which is driving further studies for ischemic
diseases more widely in China.
Monomers and Active Components of
Medicinal Plants
Replenishing and Activating Blood
Salvianolic acids
Radix Salvia miltiorrhiza (Danshen) is one of the typical
blood-activating and stasis-resolving medicines and it offers
therapeutic promise for cardiovascular diseases (Wang et al.,
2014). Salvianolic acids are the maximum water extraction from
Danshen including salvianolic acid A (Sal A) and salvianolic
acid B (Sal B). A meta-analysis of five studies was performed to
evaluate the effects of Sal A and Sal B on myocardial infarction
rats. And it showed that Sal A and Sal B both increased
blood vessel density in MI rats (Yu et al., 2017). Another trial
identified the anti-apoptotic effects of Sal A against ischemic
reperfusion injury in diabetic rats. Sal A has similar actions as a
JNK inhibitor through down-regulating JNK/PI3K/Akt pathway
(Chen et al., 2016). Stem cells may be the targets of Sal A and
Sal B to improve cardiac function and promote angiogenesis.
Li et al. (2014) found that Sal A exerted cardioprotection by
increasing capillary density in ischemic rat myocardium detected
by CD31 staining. Sal A enhanced the activity of endothelial
progenitor cells (EPCs) through SDF-1α/CXCR4 axis (Li et al.,
2014). In vitro experiments showed that Sal B pretreatment could
promote MSC differentiated into endothelial cells. Thus injection
of Sal B pretreated MSCs improved myocardial infarction in rats
by promoting angiogenesis (Guo et al., 2014). Taken together,
these findings all illustrate that salvianolic acids could effectively
promote cardioprotection in pre-clinical models of IHDs.
Tanshinone IIA
Vascular endothelial growth factor is a pivotal pro-angiogenic
factor. The transcriptional factor, HIF-1 enhances VEGF
expression in response to hypoxia and plays an important role
relating to angiogenesis (Hong et al., 2004). Tanshinone IIA (Tan
IIA) is the most abundant diterpene quinone in Danshen. Sodium
tanshinone IIA asylate injection is used to treat cardiac infarction
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in China. Tan IIA elicited significant cardioprotective effects by
promoting angiogenesis in MI rat model. Tan IIA improved heart
function, reduced infarct size and enhanced VEGF and hypoxia-
inducible factor 1alpha (HIF-1) mRNA expression (Xu et al.,
2009).
Ferulaic acid
Ferulaic acid is the main component of Radix Angelica Sinensis.
Bone marrow stromal cells (BM-MSCs) play crucial roles in
angiogenesis (Fukuda et al., 2004). In vitro, BM-MSCs were
pre-treated with sodium ferulate and n-butylidenephthalide.
Then transplantation of pre-treated BM-MSCs into the ischemic
stroke zone promoted VEGF production and angiogenesis by
AKT/mTOR signaling pathway (Zhang Q. et al., 2017). Liu et al.
(2009) synthetized a compound called acetyl ferulaic isosorbide
(AFI) by the esterification of ferulaic acid and isosorbide
mononitrate. AFI showed protective effects in myocardial
ischemia/reperfusion (MI/R), however, the protective cellular
mechanism have yet to be revealed (Liu et al., 2009).
Invigorating and Replenishing Qi
Rhodiola
Rhodiola may relieve MI injury by improving angiogenesis in
ischemic myocardium. Rhodiola up-regulated the expression
of Flt-1 and Tie-2 in ischemic cardiac zone which are related
to angiogenesis (Li et al., 2005). Flt-1, also known as VEGF
receptor-1 (VEGFR-1) is a kind of tyrosine kinase. VEGF
initiates the angiogenesis process via the activation of VEGFR-1
and VEGFR2 (Cudmore et al., 2012). Tie-2 is the receptor
of angiopoietins. Angiopoietins-Ties axis are required for the
formation of blood vessels (Hennings et al., 2016). A different
study described in acute myocardial infarction rats, Radix et
Rhizoma Rhodiolae Kirilowii may promote angiogenesis through
stimulating HIF-1a, HIF-1β and VEGF. The expression of vWF, a
marker of endothelial cells was also significantly increased (Gao
et al., 2009).
Salidroside
Salidroside is an active compound extracted from Rhodiola
and it has been reported that intramuscular administration of
salidroside robustly enhanced blood perfusion recovery in hind-
limb ischemia mice (Zhang J. et al., 2017). The beneficial effect of
salidroside in peripheral artery disease may be extended to use in
IHD and would need to be explored further.
Astragalosides
Astragaloside (AST), is the total saponin fraction isolated from
Astragalus membranaceus (Fisch) (Wang et al., 2002) and has
been used to develop drugs for therapeutics of cardiovascular
diseases. AST promoted VEGF and bFGF expression which may
contribute to increase in angiogenesis in rat models of myocardial
infarction (Yu et al., 2015).
Other Active Components of Medicinal Plants
Berberine
Berberine is an alkaloid extracted from Berberis and Berberis
aristata and has apparent preventive effects on cardiovascular
diseases. Zhu et al. (2017) conducted the myocardial infarction
(MI) surgery in mice fed with 100 mg/kg/day berberine. Two
weeks after surgery, berberine significantly improved cardiac
function and increased angiogenesis. Mice treated with berberine
had increased expression of miR-29b. The protective effects of
berberine were reversed by antagonism of miR-29b in human
umbilical endothelial cells in vitro (Zhu et al., 2017). In contrast,
reports suggest that miR-29b inhibits angiogenesis by targeting
VEGF-A in endometrial carcinoma (Chen et al., 2017). MiR-
29b also attenuated angiogenesis and tumorigenesis by directly
targeting Akt3 (Li et al., 2017) or BCL2L2 (Chung et al., 2015).
However, the role of miR-29b in angiogenesis may depend upon
the cell type and pathophysiological setting such as ischemia.
Puerarin
Puerarin is a major effective ingredient extracted from the
traditional Chinese medicine ge-gen (radix puerariae). Puerarin
treatment (120 mg/kg, i.p.) reduced infarct size and promoted
angiogenesis in the ischemic heart of rats with myocardial
infarction. The cellular mechanism maybe via promotion of the
expression of VEGF and eNOS (Zhang S. et al., 2006).
Extract of Geum japonicum
Li et al. (2006) isolated bioactivate fraction from Chinese herb
Geum japonicum. In vitro, they screened and mixed the fractions
that could stimulate angiogenesis and cardiomyogenesis. In vivo,
the mixed fractions decreased infarct size, stimulate early
development of new blood vessels and regenerate myocardium
(Li et al., 2006).
Chinese Herbal Formula
Chinese herbal formula has been reported to be effective in
promoting angiogenesis in endothelial cells during intracerebral
hemorrhage (REF). Therefore, whether Chinese herbal formula
can have protective effects during IHD is yet to be established.
Danggui Buxue Tang (DBT)
Danggui Buxue Tang (DBT) is a classic Chinese herbal formula
which consists of Astragali mongholici Radix and Angelica
sinensis Radix (ASR). DBT may enhance angiogenesis and relieve
endothelial dysfunction induced by lysophosphatidyl choline
(Lin et al., 2017).
Xuefu Zhuyu Tang (XFZYT)
Xuefu Zhuyu Tang (XFZYT) is composed of peach kernel,
saﬄower, angelica, chuanqiong, radix paeoniae rubra and other
11 kinds of natural compounds. XFZYT induced ECV304
endothelial cell proliferation, migration, and angiogenesis by
up-regulating VEGF-VEGFR2 pathway. This could potentially
explain how XFZYT may have the potential to promote
angiogenesis in IHD (Gao et al., 2012).
Buyang Huanwu Tang (BYHWT)
Angiogenesis following intracerebral hemorrhage plays an
essential role in maintaining brain functional and ultimately
recovery. BYHWT treated mice exhibited increased vessels in the
brain and enhanced VEGFR2 phosphorylation in brain micro
vessels by PI3K/Akt signaling pathway (Cui et al., 2015).
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Chinese Patent Drugs
Shexiang Baoxin Pills
Shexiang Baoxin pills (SBPs) may partially participate in
angiogenesis. Atherosclerosis and myocardial infarction rabbit
models were established by Shen et al. (2010). High-fat diet
accompanied with SBP was fed. Echocardiography results showed
that SBP could improve cardiac functions. CD34 positive staining
and increased VEGF and VEGFR-2 expressions indicated that
SBP promoted angiogenesis (Shen et al., 2010). Another paper
dived more deeply into the protective mechanism of SBPs. It may
be mediated via up-regulation of 20-hydroxyeicosatetraenoic
acid (20-HETE). HET0016 could inhibit the biosynthesis of
20-HETE and it could reverse the protective effects of SBPs
on myocardial infarction. What’s more, SBP could promote
circulating EPCs mobilization and VEGF expression (Huang
et al., 2017).
QI-SHEN-YI-QI
QI-SHEN-YI-QI formula consists of astragalus, danshen,
panax notoginseng, and dalbergia. Clinically, QI-SHEN-
YI-QI formula was widely used to treat angina. Modern
pharmacological studies show that QSYQ significantly decreased
infarct area, and promoted microvessel density during 7 days
in ischemic rats with left anterior descending artery (LAD)
ligation. QSYQ treatment group induced the increased mRNA
and proteins of VEGF, bFGF and PDGF-B (Zhang et al.,
2010). In microvascular endothelial cells, Dai GH found
that Qi-Shen-Yi-Qi Dripping Pills could promote the ECs
migration and tube formation. miRNA chip and qPCR
techniques were used to analyze the expression of miRNA and
found that miR-223-3p was the target of QSYQ (Dai et al.,
2016).
Tongxinluo (TXL)
Tongxinluo has the effects of promoting Qi, activating blood
and dredging collaterals to relieve pain. Cardiac microvascular
endothelial cells (CMECs) stimulated by Tongxinluo secreted
more cytokines who were involved in CMECs proliferation,
growth and differentiation, as well as chemotaxis and
transport in ischemia/reperfusion injury. Among them,
PDGF, bFGF, ANG-1, and VEGF all increased which means
that Tongxinluo may be associated with angiogenesis (Cui et al.,
2016).
Xuesetong Soft Capsules
Xuesetong soft capsules is composed of Notoginseng total
Saponins. Wang et al. (2012) constructed the classical
acute myocardial infarction rat models. Xuesetong soft
capsules were fed for 6 weeks. Delightingly, Xuesetong soft
capsules treatments could accelerate angiogenesis and VEGF
mRNA expression in infarcted border zone (Wang et al.,
2012).
CONCLUSION
Ischemic heart disease is a serious threat to human health,
the incidence is continuously increasing in conjunction with
the prevalence of diabetes, metabolic disorders and the aging
population. Therapeutic angiogenesis is a promising method
in the management of IHD. Accumulating evidence in animal
models has demonstrated that blood-activating and stasis-
resolving Chinese herbal medicines have pro-angiogenic
effects, the mechanisms of which are centered around the
vascular growth factor signaling pathway. Nevertheless,
further large scale blinded randomized clinical trials are
essential to prove the effectiveness of the treatment and
clarify our understanding of the therapeutic potential. If
the traditional Chinese herbal medicines are to be used
alongside contemporary therapy the safety and efficacy
of therapeutic angiogenesis deserves more attention.
Future studies will need to extend to dosing regime,
delivery route and the safety of use alongside current drug
therapeutics.
Chinese herbal medicines are apparently effective in
the treatment of IHD because of their multi-targeting.
However, the exact pro-angiogenic mechanism of Chinese
herbal medicines still remains unclear and requires to be
fully validated. Without these steps it makes it difficult to
extend to the world. At present the understanding of the
pro-angiogenic mechanism of Chinese herbal medicines
is incomplete, and mainly focuses on the vascular growth
factors. Deeper understanding and more specific signaling
pathways need to be explored. For example, endothelial
cells (ECs) display a highly migratory and proliferative
state during vessel sprouting (Eelen et al., 2015). ECs
metabolism are involved in angiogenesis (De Bock et al.,
2013) and it may become a new candidate of Chinese
herbal medicines. Inducing stem cells to secret vascular
growth factors or form new vessels may be another
candidate. In general, to explore the mechanism and
effective molecular targets of Chinese herbal medicines are
of importance, which will provide new insights into therapeutic
angiogenesis and promote the modernization of Chinese herbal
medicines.
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